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The production of IgG HLA antibodies after lung transplantation (LTx) is considered to be a major risk factor for the development
of chronic rejection, represented by the bronchiolitis obliterans syndrome (BOS). It has recently been observed that elevated
levels of IgM HLA antibodies also correlates with the development of chronic rejection in heart and kidney transplantation. This
study investigates the relationship between IgM and IgG antibodies against HLA and MICA after lung transplantation. Serum was
collected from 49 patients once prior to transplantation and monthly for up to 1 year after lung transplantation was analyzed
by Luminex to detect IgM and IgG antibodies against HLA and MICA. The presence of either IgM or IgG HLA and/or MICA
antibodies prior to or after transplantation was not related to survival, gender, primary disease, or the development of BOS.
Additionally, the production of IgG alloantibodies was not preceded by an increase in levels of IgM, and IgM levels were not
followed by an increase in IgG. Under current immune suppressive regimen, although the presence of IgM antibodies does not
correlate with BOS after LTx, IgMhigh IgGlow HLA class I antibody titers were observed more in patients with BOS compared to
patients without BOS.
1.Introduction
The bronchiolitis obliterans syndrome (BOS) represents
chronic rejection that accounts for the majority of mortality
after lung transplantation (LTx). Almost 50% of lung trans-
plant recipients develop BOS within ﬁve years after LTx [1–
3]. BOS consists of damage and ﬁbrosis within the airways,
leading to decreased lung function which is used to diagnose
chronic rejection after LTx [4]. Although the mechanisms
underlying the pathogenesis of BOS remain unclear, several
risk factors have been identiﬁed. The appearance of IgG
antibodies against human leukocyte antigens (HLA) after
lung transplantation is one of the major risk factors for
chronic rejection [5–8].
The presence of IgG anti-HLA in patient sera reac-
tive with antigens present on the donor lung prior to
transplantation is a contraindication for transplantation
[9, 10]. The majority of HLA diagnostics identify HLA
antibody speciﬁcity prior to or after transplantation of the
IgG isotype. The presence of this isotype is indicative of T-
cell reactivity, as T cells are required to facilitate the isotype
switch from IgM to IgG. Current immune suppressive
regimensusedaftertransplantationarefocusedoninhibiting
T-cell function, including help for isotype switching [11].
We recently described the absence of IgG anti-HLA after
lung transplantation when patients were treated with a
tacrolimus/mycophenolate mofetil immunosuppressive reg-
imen [12]. Therefore, we hypothesize that the low levels of
IgG antibodies observed during this regimen may be the
result of repression of IgM to IgG class switching. IgM anti-
bodies develop early during the immune response and are
able to ﬁx complement eﬃciently. Although the presence of2 Pulmonary Medicine
IgM antibodies prior to or after transplantation was initially
considered to be harmless, it has recently been demonstrated
that the presence of these antibodies in heart or kidney
transplant patients may be predictive of rejection [13].
The goal of this study was to determine the relationship
between IgM HLA antibodies after lung transplantation
and the development of BOS. Additionally, we examined
whether a correlation existed between IgM and IgG HLA
antibodies after lung transplantation to determine if the
isotype switch is inhibited by the immune suppressive
regimen of tacrolimus/mycophenolate mofetil.
2. Methods
2.1. Patients. A total of 49 LTx patients transplanted between
September 2003 and March 2008 at the Heart Lung Centre in
Utrecht, The Netherlands, who exhibited a greater than three
months survival, were included in this study. Eleven patients
developed BOS during followup. BOS was deﬁned as an
irreversible decline in FEV1 of more than 20% compared to
thepostoperativebaselineintheabsenceofinfectionorother
etiology [14, 15]. Standard immunosuppressive therapy
consistedofbasiliximab,tacrolimus,mycophenolate-mofetil,
and prednisone. No standard surveillance bronchoscopies
were performed. In patients where a decline in lung function
wasobserved,infectionswerediagnosedbyculturesorBALF,
and PCR was used for the diagnosis of CMV and EBV.
When infections were excluded as the cause of FEV1 decline,
patients were treated with corticosteroids and azithromycin.
The study design was approved by the medical ethical
committee. Informed consent was obtained from each
patient. Patients donated blood every month during the ﬁrst
yearaftertransplantationandonceeverythreemonthsinthe
following years.
2.2. HLA Antibodies. Sera of 49 patients with known HLA
type were screened for the presence of anti-HLA and
anti-MICA antibodies prior to transplantation and then
longitudinally, with an average of 20.7 months (range 10–29
months), after transplantation. A total of 382 samples were
analyzed for IgG, and 477 samples were analyzed for IgM
antibodies against HLA using Luminex beads according to
themanufacturer’sprotocol(LABScreenMixed,LSM12,One
Lambda). For the IgM assay, the IgG detecting antibody was
replaced with an IgM detecting antibody (R-phycoerythrin-
conjugated AﬃniPure F(ab) Fragment Donkey anti-human
IgM obtained from Jackson ImmunoResearch). Three hun-
dred eighty-two samples obtained from 49 patients were
analyzed for both IgG and IgM.
The IgM tests were validated by measurement of 30
unimmunized males and measurements of samples obtained
from kidney transplantation patients known to have high
titers of IgM using both ELISA and Luminex. Optimal serum
dilutions, conjugate dilutions, and incubation times were
determined.
2.3. Depletion of IgM from Sera. Dithiothreitol (DTT) was
used to deplete serum IgM as previously described [16]. Sera
were incubated with an equal volume of 0.01M DTT for 30
minutes at 37◦C before testing as described above. A negative
control (sample containing high levels of IgG and no IgM
that was treated with DTT) and a positive control (sample
containing high IgM and no DTT) were included in addition
to sera that were diluted with PBS and not depleted of IgM
by DTT.
2.4. Deﬁnition of Antibody Positivity. Positivity for IgG anti-
HLA or -MICA was deﬁned using the default settings of
the software (Fusion) provided by the manufacturer (One
Lambda). For IgM-positive HLA and MICA antibodies, a
threshold was deﬁned. Thirty healthy HLA-unimmunized
males were analyzed to determine background levels. For
each bead, the average background, including the range
and standard deviation, was determined in these healthy
controls.Apatientwasconsideredtohavepositiveantibodies
whenthemeanﬂuorescentintensity(MFI)(correctedforthe
negative bead) was >5 times the average background MFI of
the unimmunized males.
Titers of IgM and IgG antibodies were deﬁned as
IgMhigh/IgMlow when MFI values were above or below
the overall average of all beads in thirty healthy HLA-
unimmunized males or IgGhigh/IgGlow w h e nM F Il e v e l sw e r e
above or below the average background levels of all beads for
IgG as deﬁned by the manufacturer.
2.5. Possible Donor-Speciﬁc Antigens and Third-Party Anti-
gens. For each patient, it was determined which beads
contained at least 1 antigen from a mismatched donor
HLA. These beads were considered to possess possible
donor-speciﬁc antigens (DSA). Beads that were negative for
mismatched donor HLA antigens were identiﬁed as third-
party antigens (TPA).
2.6. Statistics. A P value of < 0.05 was considered to be
signiﬁcant. For correlation analysis, a P value of < 0.05
combined with −0.4 ≤ r ≥ 0.4 was considered signiﬁcant.
Correlations were analyzed using spearman rank correlation
analysis, and diﬀerences in patient characteristics were
analyzed by Mann-Whitney rank-sum, Fisher exact, or chi-
square tests. These tests were also used to analyze diﬀerences
in IgM and IgG titers between patients with and without
BOS.
3. Results
3.1. Patient Characteristics. This study involved 49 patients
whose details are displayed in Table 1. Four patients died as
a result of BOS, and 1 patient died due to other causes. As
expected, the mortality rate was higher in patients diagnosed
with BOS compared to patients without BOS (P = 0.02,
Fisher exact test). It should be noted that the group of
BOS patients did not diﬀer from the patients without BOS
with respect to gender, age, primary disease, type of graft,
ischemic time, or HLA mismatches for class I and class
II. The average onset of BOS was 22.5 months after lung
transplantation.Pulmonary Medicine 3
Table 1: Patient characteristics.
BOS Non-BOS
Total number 11 38
Deceased 4 (36%) 1 (3%)
Gender
Male 3 (27%) 22 (58%)
Female 8 (73%) 16 (42%)
Average age (years; SD) 45 (+15) 42 (+13)
Primary disease
CF 3 (27%) 19 (50%)
EMF 5 (46%) 9 (24%)
FD 3 (27%) 10 (26%)
Type of graft
Single 2 (18%) 4 (11%)
Bilateral 9 (82%) 34 (89%)
Average ischemic time (minutes; SD)
Single 216 (±70) 209 (±43)
Bilateral 317 (±51) 322 (±72)
HLA mismatches (average; SD)
Class I 3.6 (±0.7) 3.1 (±0.7)
Class II 1.7 (±0.5) 1.7 (±0.5)
BOS onset (months; SD) 22.5 (±13.9) ND
BOS grade
I 3 (27%) ND
II 2 (18%)
III 6 (55%)
BOS: bronchiolitis obliterans syndrome, SD: standard deviation, CF: cystic
ﬁbrosis, EMF: emphysema, and FD: ﬁbrotic disease.
3.2. Presence of Antibodies before and after Transplantation.
Weobtainedserumfrom41patientspriortotransplantation.
Twelve of these patients tested positive for IgM anti-HLA
class-I and/or class-II, and 5 patients tested positive for
IgG HLA class I or II antibodies, indicating that IgM
antibodies against HLA occurred more frequently in our
study population compared to IgG antibodies. Additionally,
antibodies against MICA were more frequently of the IgM
isotype (n = 7) compared with the IgG (n = 2) isotype.
After transplantation, serum was collected monthly from 49
patients. It was observed that antibodies against HLA class
I and/or class II were more frequently of the IgG (n = 23)
isotype than of the IgM (n = 16) isotype. MICA antibodies,
however, were more frequently of the IgM (n = 14) isotype
(IgG,n = 7).Norelationshipwasobservedbetweenpresence
of antibodies before and after lung transplantation. The
majority of patients who, prior to LTx, have antibodies
against HLA or MICA also express these antibodies after
transplantation.Someoftheseantibodiesarenotpersistently
reactive with the same HLA-coated Luminex beads, and
some patients expressing antibodies prior to LTx do not
express them after LTx. In 25 patients, de novo antibodies
against HLA or MICA appeared after transplantation, with
an average ﬁrst appearance after transplantation at 7.5
months (HLA class I), 17.6 months (HLA class II), and 8.4
months (MICA). A longitudinal analysis was performed to
determine if speciﬁc patterns in the elevation or reduction of
titerscouldbeobserved.Although,onaverage,lowbutstable
titers of HLA class I, class II, and MICA IgM antibodies were
detected after LTx, average titers were elevated compared to
background titers (Figure 1). The MFI levels of 30 healthy
unimmunized males were used to establish the background
levels. For HLA class I, an average background MFI of 107
was observed, while LTx patients on average exhibited an
MFI of 186. For HLA class II, a background level MFI of 62
was observed, while the LTx patient average was an MFI of
96. MICA titers were highest in LTx patients as compared to
HLA classes I and II. MFI was 385 in LTx patients compared
with a background of MFI 148 observed in unimmunized
healthy males. MFI levels of the 3 antibody groups were
relatively stable after LTx. Although a peak in the levels of
MICA antibody was observed in the 8th quarter after LTx,
thiswastheresultofalowsamplenumberinthatquarterand
1patientexhibitingahightiterofMICAantibodiesafterLTx.
3.3. Correlation between IgM and IgG Antibodies and Isotype
Switching. A total of 341 serum samples taken after LTx were
analyzed for both HLA and MICA antibodies of IgM and
IgG isotype, with a total of 12,958 bead-serum combinations
being measured. The MFI values of beads containing either
HLA class I, HLA class II, or MICA antigens are displayed
in Figure 2, with each dot representing MFI values derived
from IgM/IgG assays of 1 Luminex bead tested against 1
serum. Average background values for IgM and IgG are
displayed as grey bars, with each graph divided into four
quadrants. In Figure 2(a), the correlation between IgM and
IgG for HLA class I after transplantation is indicated by
8,182 bead measurements. Most samples titers of IgM and
IgG are near background levels. Although some sera show
elevated titers for either IgM or IgG; almost no sample is
positive for both IgM and IgG. A small percentageof the data
points did exhibit elevated IgM and extremely elevated IgG
MFI values; however, these data were all derived from the
same individual. This was a female (40 years) who already
exhibited elevated MFI values prior to transplantation and
had also experienced two pregnancies. As fewer beads in the
kit are coated with HLA class II or MICA antigens, graphs
depicting the results of these studies contain a reduced
number of data points (Figures 2(b) and 2(c),r e s p . ) .I n
agreement with previous results, samples containing both
IgM and IgG antibodies against HLA class-II antigens were
rare. This was also observed in studies of antibodies against
MICA. These ﬁndings indicate no correlation between IgM
and IgG levels of anti-HLA class I, II or MICA antibodies
after LTx. The majority (approximately 80%) of samples
exhibit an average or low MFI compared to the average
background observed in unimmunized controls (Figures
2(a), 2(b),a n d2(c)).
To investigate whether the lack of positivity for IgG anti-
HLA antibodies may result from the physical inhibition by
IgManti-HLAantibodybindingtothebeads,10serasamples
exhibiting elevated levels of MFI speciﬁc for IgM anti-HLA
class I antibodies were selected and treated with DTT to
disrupt IgM. One sample exhibiting high IgG MFI levels
and low expression of IgM was used. IgM anti-HLA was not4 Pulmonary Medicine
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Figure 1: Average mean ﬂuorescent intensity (MFI) of IgM isotype HLA class I, class II and MICA antibodies over time (a quarter is
equal to 4 months). Forty-one patients were analyzed once prior to LTx, and 49 patients were measured longitudinally after transplantation
resulting in a total of 477 samples that were analyzed by Luminex (LABScreen Mixed, LSM12, One Lambda, Calif, USA), with an average
of 9.7 samples (range 5–10 samples) per patient. Shown are results of Luminex analysis with beads containing HLA class I (closed dot)
class II (closed square), or MICA antigens (triangle with dotted line). These data were averaged from all LTx patients per quarter after lung
transplantation.
detected following incubation with DTT, and MFI levels of
IgG anti-HLA did not increase. The IgG anti-HLA control
sample still exhibited elevated MFI values following DTT
treatment, indicating that IgG binding was not impaired by
DTT (data not shown). Given these ﬁndings, the lack of IgG
anti-HLA detection in serum samples with IgM anti-HLA
antibodies is not the result of inhibition by antibodies of the
IgM isotype.
In samples containing elevated levels of IgM or IgG
antibodiesagainstHLA,itwasinvestigatedwhetherhighIgM
was followed in time by high IgG or whether high IgG was
preceded by high IgM. To this end, beads were identiﬁed
recognized by patient sera and the other sera collected
from the same patients at other time points were analyzed
for reactivity against the same beads. Figure 3 illustrates
a longitudinal analysis recognition of a speciﬁc bead by
IgM and IgG anti-HLA antibodies. Figure 3(a) provides
an example of high IgM levels which are not followed by
IgG through the means of isotype switching, as IgG levels
remain very low. Figure 3(b) indicates that elevated levels of
IgG are not preceded by high IgM expression. Longitudinal
analysis of all sera exhibiting either high IgM or IgG MFI
values provided comparable results, indicating that, in these
samples of lung transplant patients; there is no relation
between IgM and IgG antibodies against HLA or MICA.
3.4. Relation between Clinical Parameters, Antibodies, and
Antibody Titers. We next investigated if clinical characteris-
tics were related to IgM or IgG anti-HLA antibodies present
prior to lung transplantation. There was no diﬀerence in
the gender of patients that tested positive for IgM or
IgG isotype HLA antibodies prior to transplantation. The
percentageofmalesexpressingIgMantibodies againstMICA
prior to transplantation was slightly higher than that of
females (P = 0.09, ﬁsher exact test). Patients lacking IgM
antibodies were younger than patients expressing MICAPulmonary Medicine 5
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Figure 2: Correlation plots of IgM and IgG HLA class I (a), HLA class II (b), and MICA (c) antibodies after LTx. Grey lines represent the
average background as detected in 27 unimmunized males (IgM) or as deﬁned by the manufacturer (IgG). The background range of the
individual beads is displayed by the grey area.
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Figure 3: Examples of no correlation between levels of IgM and IgG anti-HLA. Elevated levels of IgM are not followed in time by high levels
of IgG levels (a), and increased levels of IgG are not preceded by high levels of IgM (b). Figures are indicative of 1 bead obtained from 1
patient in time.6 Pulmonary Medicine
IgM antibodies (P = 0.04, Mann-Whitney rank-sum test).
Transplant patients suﬀering from end-stage cystic ﬁbrosis
prior to LTx were younger than patients diagnosed with
emphysema or ﬁbrotic diseases. These cystic ﬁbrosis patients
exhibited reduced levels of IgM antibodies compared to the
other patients (P = 0.014, chi-square) and, also, showed a
reduction in HLA class I and/or class II IgM antibodies (P =
0.002,chisquare).Thesediﬀerencesinclinicalcharacteristics
in patients with and without IgM antibodies were not
observed after lung transplantation.
Analysis of antibody titers after LTx indicated no rela-
tionship to the development of BOS (data not shown), as
no rise or fall in antibody titers was observed prior to BOS
diagnosis. The presence of IgM or IgG antibodies against
HLA class I, HLA class II, and/or MICA prior to or after
lung transplantation is not related to the development of
BOS. Donor-speciﬁc antibodies may better correlate with
development of BOS, so we designated DSA for beads
with possible donor-speciﬁc antigens and TPA beads lacking
these antigens. Our results indicated no diﬀerences between
patients with BOS and without BOS for IgM anti-HLA,
although a trend was observed in patients lacking IgG
anti-HLA, as they developed BOS with a higher frequency
(P = 0.06, Kaplan Meyer test; data not shown). To examine
whether diﬀerences observed between BOS and non-BOS
patients were correlated with antibody titers, all data points
wereplottedinseparatecorrelationgraphs.Weobservedthat
themajorityofthesamplesobtainedfrompatientseventually
diagnosed with BOS were below IgG background levels
(Figure 4(b)), while elevated antibody titers were detected in
patients that do not develop BOS (Figure 4(a)). By contrast,
patients diagnosed with BOS had relatively more samples
with high IgM titers (Figure 4(b)) compared to non-BOS
patients (Figure 4(a)). To quantify this, we determined the
number of samples possessing IgMlow IgGlow,I g M high IgGlow,
IgMlow IgGhigh,o rI g M high IgGhigh antibody titers. In BOS
patients,66%ofthesampleswereIgMhigh while52%samples
of patients without BOS had high IgM titers (P = 0.04, ﬁsher
exact test). Diﬀerences in IgG antibody titers were more
deﬁned, with only 14% of BOS patients exhibiting elevated
IgG antibody titers versus 54% of the samples from non-
BOS patients (P ≤ 0.0001, ﬁsher exact test). For HLA class
II, there was no observable diﬀerence between BOS and non-
BOS patients. Analysis using DSA and TPA coated beads also
did not indicate any diﬀerences. In Figures 5(a) and 2(b), the
mean ﬂuorescent intensity of IgG or IgM isotype HLA class I
antibodies is displayed, showing that there are no diﬀerences
between total of HLA class I antibodies and the possible DSA
HLA class I antibodies. However, diﬀerences between BOS
patients and non-BOS patients become clear; an increase is
seen in the titers of IgG HLA class I antibodies of non-BOS
patientscomparedtoBOSpatients,whileadecreaseisshown
for titers of IgM HLA class I antibodies of non-BOS patients
compared to BOS patients.
4. Discussion
In this study, we demonstrate that the presence of IgM HLA
and MICA antibodies prior to or after lung transplantation
is not related to the development of BOS. We also show
that the course of IgM antibody titers is stable after lung
transplantation. After LTx, there is no correlation between
IgM and IgG antibodies, as high IgM is not followed by
high IgG and high IgG is not preceded by IgM. Patients
diagnosed with BOS, however, do exhibit elevated HLA class
I IgM antibody titers and low IgG titers compared to patients
without BOS.
IgM antibodies against HLA have been considered to
be clinically irrelevant, but recent ﬁndings challenge this
concept. In heart transplantation, it was shown that non-
HLA antibodies of IgM isotype were correlated with a
r e d u c t i o ni ng r a f ts u r v i v a l[ 13, 17]. In the context of heart
and kidney transplantation, it has also been demonstrated
that expression of HLA antibodies of the IgM isotype corre-
lates with transplant rejection [13]. The sensitive Luminex
method used in this study made it possible to detect the
presence of low HLA IgM antibody titers. Consistent with
the results of HLA IgG antibody studies, no relationship
could be detected between the presence of low HLA IgM
antibody titers and chronic rejection or overall survival
in patients treated with an immune suppressive regimen
consisting of tacrolimus and mycophenolate mofetil after
lung transplantation [12]. In concert with this, a study of
kidney transplantation also showed that low titers of DSA
HLA IgG antibodies present prior to transplantation are not
detrimental to overall survival and do not correlate with
acute or chronic rejection [18].
One study detected a correlation between MICA anti-
bodies and development of rejection after kidney trans-
plantation. However, a number of other studies of heart
or kidney transplantation did not ﬁnd such a relation [19–
22]. Although MICA antibodies appear to contain minor
complement ﬁxing abilities, MICA is expressed in high levels
in the renal system and intestines and is not detected in
the heart or aorta, raising the possibility that the ability of
these antibodies to bind complement to induce antibody-
mediated rejection is organ speciﬁc [22]. Although MICA
expression can be induced on airway epithelial cells by stress,
we observed no relationship between the presence of MICA
antibodies and the chronic rejection of graft survival. In
our study, MICA antibodies were present in both males
and females prior to transplantation, although levels were
slightly higher in males. These results and previous studies
indicate that it is unlikely that MICA antibodies develop due
to pregnancy.
High levels of IgM antibodies in serum may physically
inhibit the binding of IgG antibodies to the Luminex beads
[23]; however, experiments using DTT treatment indicated
that IgM antibodies could be depleted from the serum and
that MFI levels of IgG did not increase. This indicates that
the lack of IgGhigh antibody titers in BOS patients is not an
artifact caused by high concentrations of IgM antibodies.
Elevated levels of IgG anti-HLA that are detected after
lung transplantation are also commonly observed prior to
transplantation. The production of these antibodies is there-
fore not hampered by the immunosuppressive treatment
with tacrolimus and mycophenolate mofetil administered
after transplantation. We also observed no indication ofPulmonary Medicine 7
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Figure 4: Diﬀerences in HLA class I antibody isotype proﬁles in BOS and non-BOS patients.
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Figure 5: Mean ﬂuorescent intensities of HLA class I antibodies. (a) All HLA class I antibodies of both IgG and IgM isotype in BOS and
non-BOS patients. (b) Possible DSA HLA class I antibodies of both IgG and IgM isotype in BOS and non-BOS patients. Error bar depicts
the standard error of mean.
IgM replacement by IgG alloantibodies, suggesting a lack
of class-switching of B cells that may be due to the
immunosuppression of T cells. These ﬁndings revealed that
de novo IgG anti-HLA antibodies after lung transplantation
yielded low levels of MFI.
Although titers of HLA class I IgMhigh IgGlow antibodies
are elevated in patients with BOS, this cannot be used as a
possible marker for the development of BOS because some
patients without BOS also have antibody titers exhibiting
elevated IgM and low IgG. Additionally, although patients
without BOS express higher HLA IgG antibody levels
compared to patients with BOS, some considerations have
to be placed. First, HLA IgG antibody titers are low and
may not be capable of activating the complement cascade.
Second, it is unknown if IgG HLA antibodies are of the
IgG1, IgG3 subclasses able to ﬁx complement, or of the
IgG2 and IgG4 subclasses. If HLA antibodies are sequestered
to the transplanted lung rendering them undetectable in
BOS patients, they could ﬁx the complement system and
hence contribute to the development of BOS after lung
transplantation [13, 24, 25]. Furthermore, there are reports
that low titers of HLA antibodies may be protective instead
of harmful [22, 26]. It is also unclear if the relationship
between BOS and HLA class-I antibody levels contributes to8 Pulmonary Medicine
the disease process or is an epiphenomenon. In our assays,
we used beads with multiple antigens coated on them which
did not allow us to detect speciﬁc donor reactivity. It should
be noted that using beads speciﬁc to either DSA or TPA did
not reveal any signiﬁcant diﬀerence, and therefore a test with
single antigen beads probably does not contribute to our
ﬁndings. We also could not exclude cross-reactivity between
the antibodies.
Inconclusion,lungtransplantpatientsdevelopIgMHLA
and MICA antibodies prior to and after transplantation.
The presence of these antibodies and their titers are not
related to chronic rejection under the current immune
suppressive regime, and the isotype switch is inhibited.
Patients diagnosed with BOS, however, exhibit elevated
levels of IgM and reduced IgG HLA expression compared
to patients without BOS. HLA antibodies are thought to
be involved in chronic graft rejection as a result of their
complement ﬁxing ability as observed by C4D deposition
within the graft. Mechanistically, our data could imply that
IgM HLA antibodies are relevant to the pathogenesis of BOS
becausetheyareabletoﬁxcomplementmoreeﬃcientlythan
IgG.
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